ESR1 and breast carcinoma: In randomized clinical trials (RCTs), these drugs can lower the incidence of estrogen receptor-positive (ER+) breast cancer by 50–65%, with a relative risk reduction of ~70% in women with atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS) [1,3].